Shots: Dr. Reddy to acquire Glenmark’s brands Momat Rino (for Russia, Kazakhstan, and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan & Uzbekistan), Glenspray, and Glenspray Active (for […]readmore
Tags : Acquire
Shots: Selvita to acquire 100% of the outstanding shares in Fidelta for $37.08M + customary adjustments for net cash & working capital The acquisition will expand Selvita’s integrated drug discovery […]readmore
Shots: Merck to acquire all outstanding shares of Oncolmmune for $425 M in cash as an upfront. Additionally, Oncolmmune will receive sales-based and contingent payments on the achievement of the […]readmore
Shots: Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for $450M, making a total deal […]readmore
Shots: Merck will acquire all the outstanding shares of VelosBio for $2.75B in cash. The transaction is expected to be closed by the end of 2020 The acquisition will bolster […]readmore
Shots: Sanofi to acquire all outstanding shares of Kiadis for $6.34/ share, representing an equity value of $358.76M. The offer price represents a premium of 272% over the closing price […]readmore
Shots: Vedere Bio received $150M as upfront payments and is eligible to receive up to $130M as milestones making a total deal value of $280M. The transaction closed in Sept’2020 The […]readmore
Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common […]readmore
Shots: Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash, making a total deal value of $540M. The transaction is expected to close in late […]readmore
Shots: Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B The acquisition will expand Lilly’s R&D […]readmore